Drug manufacturer programs that help health care providers navigate reimbursement hurdles carry potential compliance risks and are of growing interest to government investigators, an industry attorney said.
Reimbursement assistance programs represent the "holy trinity" of enforcement risks, with the potential for violations under the federal False Claims Act, Anti-Kickback Statute and Health Insurance Portability and Accountability Act (HIPAA), said Jennifer